Australia's coronavirus inoculation program is based on a trio of different vaccines; the Oxford-AstraZeneca vaccine, the Pfizer-BioNTech vaccine, and the Novavax vaccine.
Initial trial results suggested the vaccine would be about 62 per cent effective in preventing the disease, compared to the 95 per cent efficacy reported by Pfizer and its German partner BioNTech.
Australia's regulatory body, The Therapeutic Goods Administration, will review results in the new year before it goes ahead with approval.
Professor Peter Collignon from the Australian National University expects Australia will be at an advantage.
With no uncontrolled spread of the coronavirus, he says Australia has the opportunity to wait and see results from vaccination programs around the world.
